Skip to content
Screener

Cytek Biosciences, Inc. CTKB Business Segments — Other segment items

Similar metrics at other companies

Broadridge Financial Solutions logo
BRTotal Reportable Segments — Other segment items
$121.4M+7.5%
Iron Mountain logo
IRMTOTAL REPORTABLE SEGMENTS — Other segment items
$938.34M+13.0%
GLW
GLWTotal Reportable Segments — Other segment items
$2.77B+16.4%
CNN
CNNETotal Reportable Segments — Other segment items
$52.3M+403%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Other segment items
$0-100%
Veradermics logo
MANEReportable Segment — Other segment items
-$2.63M-411%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$605.72M+25.6%
Enterprise value$548.91M+29.2%
P/S2.9×+0.5×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization - license & IP expense481481962974
Sales (excluding stock-based compensation)9,0427,83217,85516,438
Marketing (excluding stock-based compensation)3,3573,0665,4115,765
Research and development (excluding stock-based compensation)8,6497,40317,29015,551
General and administrative (excluding stock-based compensation)14,08810,50930,16620,644
Stock-based compensation expense5,3396,79110,20013,421
Other segment items758(5,041)1,160(8,614)
Net loss$(12,158)$(5,583)$(31,024)$(16,985)

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s business segments — other segment items?
Cytek Biosciences, Inc. (CTKB) reported business segments — other segment items of $758K in Q2 2026.
How has Cytek Biosciences, Inc.'s business segments — other segment items changed year-over-year?
Cytek Biosciences, Inc.'s business segments — other segment items increased by 115.0% year-over-year, from -$5.04M to $758K.
What is the long-term trend for Cytek Biosciences, Inc.'s business segments — other segment items?
Over 3 years (2022 to 2025), Cytek Biosciences, Inc.'s business segments — other segment items has grown at a 82.7% compound annual growth rate (CAGR), from -$4.29M to $26.15M.
What does business segments — other segment items mean?
Includes miscellaneous income or expenses that are not classified within the primary operating categories of the segment. This line item captures non-recurring or peripheral financial activities that impact the segment's overall profitability.

Ask your AI about Cytek Biosciences, Inc.'s business segments — other segment items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude